2026-04-30T06:02:55Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/252882024-11-28T14:48:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16958col_20.500.12105_16969
Repisalud
author
Benavent, Marta
author
Sastre, Javier
author
García Escobar, Ignacio
author
Segura, Angel
author
Capdevila, Jaume
author
Carmona, Alberto
author
Sevilla, Isabel
author
Alonso, Teresa
author
Crespo, Guillermo
author
García, Lourdes
author
Canal, Neus
author
de la Cruz, Guillermo
author
Gallego, Javier
2024-10-23T13:26:54Z
2024-10-23T13:26:54Z
2021-01-30
10.1186/s12955-021-01688-x
1477-7525
Health and Quality of Life Outcomes
http://hdl.handle.net/10668/17070
33516211
https://hdl.handle.net/20.500.12105/25288
Background and objective: Patient-reported outcome measures can provide clinicians with valuable information to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate the physician-perceived utility of the QLQ-GINET21 in routine clinical practice in patients with gastrointestinal neuroendocrine tumours (GI-NETs). Secondary aims were to explore the patient, clinician, and/or centre-related variables potentially associated with perceived clinical utility. Methods: Non-interventional, cross-sectional, multicentre study conducted at 34 hospitals in Spain and Portugal (NCT02853422). Patients diagnosed with GI-NETs completed two health-related quality of life (HRQoL) questionnaires (QLQ-C30, QLQ-GINET21) during a single routine visit. Physicians completed a 14-item ad hoc survey to rate the clinical utility of QLQ-GINET21 on three dimensions: 1)therapeutic and clinical decision-making, 2)doctor-patient communication, 3)questionnaire characteristics. Results: A total of 199 patients at 34 centres were enrolled by 36 participating clinicians. The highest rated dimension on the QLQ-GINET21 was questionnaire characteristics (86.9% of responses indicating "high utility"), followed by doctor-patient communication (74.4%), and therapeutic and clinical decision-making (65.8%). One physician-related variable (GI-NET patient volume > 30 patients/year) was associated with high clinical utility and two variables (older age/less experience treating GI-NETs) with low clinical utility. Conclusions: Clinician-perceived clinical utility of QLQ-GINET21 is high. Clinicians valued the instruments' capacity to provide a better understanding of patient perspectives and to identify the factors that had the largest influence on patient HRQoL.
eng
Neuroendocrine tumors
Health-related quality of life
QLQ-GINET21 questionnaire
Communication
Clinical utility
Physicians
Tumores neuroendocrinos
Calidad de Vida
Comunicación
Médicos
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
research article